The Influence of the Learning Curve on Clinical Outcomes in Balloon-Expandable versus Self-Expandable Transfemoral Transcatheter Aortic Valve Implantation.


Journal

Cardiology
ISSN: 1421-9751
Titre abrégé: Cardiology
Pays: Switzerland
ID NLM: 1266406

Informations de publication

Date de publication:
2023
Historique:
received: 15 03 2023
accepted: 28 05 2023
medline: 22 8 2023
pubmed: 7 6 2023
entrez: 6 6 2023
Statut: ppublish

Résumé

Balloon-expandable (BE) and self-expandable (SE) prostheses are the main types of devices currently used in transcatheter aortic valve implantation (TAVI). Despite the different designs, clinical practice guidelines do not make any specific recommendation on the selection of one device over the other. Most operators are trained in using both BE and SE prostheses, but operator experience with each of the two designs might influence patient outcomes. The aim of this study was to compare the immediate and mid-term clinical outcomes during the learning curve in BE versus SE TAVI. The transfemoral TAVI procedures performed in a single center between July 2017 and March 2021 were grouped according to the type of implanted prosthesis. The procedures in each group were ordered according to the case sequence number. For each patient, a minimum follow-up time of 12 months was required for inclusion in the analysis. The outcomes of the BE TAVI procedures were compared with the outcomes of the SE TAVI procedures. Clinical endpoints were defined according to the Valve Academic Research Consortium 3 (VARC-3). The median follow-up time was 28 months. Each device group included 128 patients. In the BE group, case sequence number predicted mid-term all-cause mortality at an optimal cutoff value ≤58 procedures (AUC 0.730; 95% CI: 0.644-0.805; p < 0.001), while in the SE group, the cutoff value was ≤85 procedures (AUC 0.625; 95% CI: 0.535-0.710; p = 0.04). A direct comparison of the AUC showed that case sequence number was equally adequate in predicting mid-term mortality, irrespective of prosthesis type (p = 0.11). A low case sequence number was associated with an increased rate of VARC-3 major cardiac and vascular complications (OR 0.98 95% CI: 0.96-0.99; p = 0.03) in the BE device group, and with an increased rate of post-TAVI aortic regurgitation ≥ grade II (OR 0.98; 95% CI: 0.97-0.99; p = 0.03) in the SE device group. In transfemoral TAVI, case sequence number influenced mid-term mortality irrespective of prosthesis type, but the learning curve was longer in the case of SE devices.

Identifiants

pubmed: 37279710
pii: 000531401
doi: 10.1159/000531401
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

335-346

Informations de copyright

© 2023 S. Karger AG, Basel.

Auteurs

Mihnea Istrate (M)

"Iuliu Hațieganu" University of Medicine and Pharmacy, Department of Cardiology, Cluj-Napoca, Romania.

Mihaela Ioana Dregoesc (MI)

"Iuliu Hațieganu" University of Medicine and Pharmacy, Department of Cardiology, Cluj-Napoca, Romania.
"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.

Sorana D Bolboaca (SD)

Department of Medical Informatics and Biostatistics, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Aurelia G Solomonean (AG)

"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.
Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Catalin Botis (C)

"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.

Adrian Stef (A)

"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.
Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Radu Hagiu (R)

"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.

Ștefan D C Moț (ȘDC)

"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.

Dan I Bindea (DI)

"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.
Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Alexandru Oprea (A)

"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.
Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Cătălin A Trifan (CA)

"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.
Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Adrian C Iancu (AC)

"Iuliu Hațieganu" University of Medicine and Pharmacy, Department of Cardiology, Cluj-Napoca, Romania.
"Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH